PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role-Reference-Cited by-同舟云学术

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role

Published:2016-06 Issue:6 Volume:57 Page:1086-1096
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Raal Frederick J.,Giugliano Robert P.,Sabatine Marc S.,Koren Michael J.,Blom Dirk,Seidah Nabil G.,Honarpour Narimon,Lira Armando,Xue Allen,Chiruvolu Padmaja,Jackson Simon,Di Mei,Peach Matthew,Somaratne Ransi,Wasserman Scott M.,Scott Rob,Stein Evan A.

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference44 articles.

1. The mysteries of lipoprotein(a);Utermann;Science.,1989

2. Erqou, S., S. Kaptoge, P. L. Perry, E. Di Angelantonio, A. Thompson, I. R. White, S. M. Marcovina, R. Collins, S. G. Thompson, and J. Danesh, ; Emerging Risk Factors Collaboration. 2009. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 302: 412–423.

3. B. G. Nordestgaard, M. J. Chapman, K. Ray, J. Borén, F. Andreotti, G. F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O. S. Descamps, ; European Atherosclerosis Society Consensus Panel. 2010. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31: 2844–2853.

4. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, ; PROCARDIS Consortium. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518–2528.

5. Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial;Hernández;Diabetes Metab.,2011

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition—Part one: Pleiotropic pro‐atherosclerotic effects of PCSK9;European Journal of Clinical Investigation;2024-06-26

2. Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening;2024-05-12

3. Clinical-epidemiological analysis of patients with elevated lipoprotein A in a third level hospital;Clínica e Investigación en Arteriosclerosis (English Edition);2024-05

4. The Mechanisms of PCSK9 Inhibitor Reducing Lipoprotein(a);PROG BIOCHEM BIOPHYS;2024

5. Novel Therapeutic Approaches for the Management of Elevated Lipoprotein(a): From Traditional Agents to Future Treatment Options;Life;2024-03-12